Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For ...

FDA Drug Recall #D-019-2013 — Class II — June 5, 2012

Recall Summary

Recall Number D-019-2013
Classification Class II — Moderate risk
Date Initiated June 5, 2012
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Bristol-myers Squibb Company
Location New Brunswick, NJ
Product Type Drugs
Quantity N/A

Product Description

Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 7 Tablets per Carton, 5 mg/500 mg, Rx only, Manufactured By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA, Marketed By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA and AstraZeneca Pharmaceuticals LP, Wilmington DE 19850.

Reason for Recall

Labeling; Correct labeled product miscart/mispack: Some Physician sample cartons were incorrectly labeled as Kombiglyze XR 2.5mg/1000mg on the external package carton, whereas the contents were Kombiglyze XR 5 mg/500 mg blister packaged tablets. The individual blister units are labeled correctly.

Distribution Pattern

Nationwide

Lot / Code Information

Lot # 1J6024PA, 1J6025PA Exp. 09/13; 1K6049PA Exp. 10/13; 1L9015WA Exp. 11/13

Other Recalls from Bristol-myers Squibb Company

Recall # Classification Product Date
D-0097-2026 Class II Opdualag (nivolumab and relatlimab-rmbw) inject... Oct 21, 2025
D-0959-2017 Class I EliquisTablets 5mg, 60 count bottle, Rx Only, M... Jun 5, 2017
D-012-2013 Class I BiCNU (Carmustine for injection) 100 mg and Di... Aug 29, 2012
D-018-2013 Class II Kombiglyze XR (saxagliptin and metformin HCl ex... Jun 5, 2012

Frequently Asked Questions

Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.